An Exploratory Phase II, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Pertuzumab and Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer

Trial Profile

An Exploratory Phase II, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Pertuzumab and Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 20 Jul 2016 Study design changed from single group assignment to parallel group assignment and treatment arms changed from 1 to 2.
    • 01 Apr 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 07 Oct 2013 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top